TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Incomplete Abortion With 600 Mcg Oral Misoprostol Compared to Standard Surgical Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* past or present history of vaginal bleeding during pregnancy~* open cervical os~* evidence of incomplete abortion with substantial debris in the uterus (if using ultrasound)~* surgical evacuation of the uterus would be advised as course of action if misoprostol was not available~* generally in good health~* woman lives or works within one hour of study site~* woman willing to provide contact information for follow up purposes~* informed consent given~Exclusion Criteria:~* contraindications to study drug~* uterine size larger than 12 weeks LMP~* signs of severe infection

- Gender: FEMALE
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Misoprostol (Type: EXPERIMENTAL): Group 1 randomized to take single dose of 600 mcg oral misoprostol
- Surgical treatment (Type: OTHER): Group 2 randomized to receive standard surgical treatment as per local protocol (D\&C or MVA)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MOSAIC - Multicenter International Study of Oxaliplatin/ 5FU-LV in the Adjuvant Treatment of Colon Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Main selection criteria:~* Histologically proven stage Dukes  B2  (stage II: T3-T4 N0 M0) and  C  (stage III: any T N1-2 M0) colon carcinoma. The inferior pole of the tumor must be above the peritoneal reflection (\> 15 cm from the anal margin)·~* Complete resection of the primary tumor without gross or microscopic evidence of residual disease~* Treatment within 7 weeks following surgery~* Age 18-75 years old~* ECOG PS £ 2~* No prior chemo, immuno or radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating Myocardial Injury for Defibrillation Threshold Testing Methods for ICD Implantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients eligible to receive an ICD implant or change out.~* Patients with a single or dual coil right ventricle (RV) defibrillation lead located in the RV apex.~* Patients greater than 18 years of age.~* Patients willing and able to give informed consent.~* Patients who have insurance which may cover additional hospital stay if myocardial injury resulted from testing~Exclusion Criteria:~* Patients with medical conditions that would limit study participation.~* Patients that are pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard Defibrillation Testing (Type: ACTIVE_COMPARATOR): Standard Defibrillation Threshold Testing is a procedure in which a low energy shock will be delivered to the heart to induce ventricular fibrillation (VF) followed by a rescue shock to restore sinus rhythm. Process is repeated after 5 minutes.
- Upper Limit of VulnerabilityTesting (Type: ACTIVE_COMPARATOR): Upper Limit of Vulnerability Testing is a procedure in which four 18J shocks will be delivered at specified intervals. If VF is induced, then a 25 J rescue shock will be delivered.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women at least 16 years of age (or minimum age as determined by local regulatory authorities)~* HIV-1 RNA viral load of greater than or equal to 2, 000 copies/mL~* A negative urine pregnancy test at the baseline visit for Women of Child Bearing Potential (WOCBP)~* Effective barrier contraception for WOCBP and males~Exclusion Criteria:~* Suspected or documented active, untreated HIV-1 related opportunistic infection (OI) or other condition requiring acute therapy~* Treatment for an active opportunistic infection, or unexplained temperature \>38.5 degrees Celsius for 7 consecutive days~* Prior treatment with efavirenz, zidovudine or lamivudine or with any other antiretroviral therapy for more than 14 days at any time~* Active alcohol or substance abuse sufficient, in the Investigator's judgment, to prevent adherence to study medication and/or follow up~* Lactating women, or planned pregnancy during the trial period~* Suspected primary (acute) HIV-1 infection~* Previous therapy with a potentially myelosuppressive, neurotoxic, hepatotoxic and/or cytotoxic agent within 30 days prior to randomization or the expected need for such therapy during the study period~* Documented or suspected acute hepatitis or pancreatitis within 30 days prior to randomization~* Significantly elevated liver enzymes or cirrhosis~* Significant neutropenia, anemia or thrombocytopenia~* Malabsorption or an inability to tolerate oral medications~* Symptomatic postural hypotension or severe cardiovascular or cerebrovascular disease~* Certain medications~* Genotypic or phenotypic resistance to efavirenz, zidovudine or lamivudine~* X4- or dual/mixed-tropic virus or repeated assay failure~* Any other clinical condition that, in the Investigator's judgement, would potentially compromise study compliance or the ability to evaluate safety/efficacy

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 3 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: EXPERIMENTAL): Following a review of the interim analysis data, the DSMB recommended to terminate the UK-427,857 300 mg QD arm based on pre-specified protocol non-inferiority criteria not being met for the QD arm versus efavirenz

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients with mild to moderate hypertension, untreated or currently taking antihypertensive therapy~* treated patients (using antihypertensive drugs within 4 weeks prior to first visit) must have an office msSBP ≥ 145 mmHg and \< 180 mmHg after washout epoch and after 4 weeks run-in epoch~* untreated patients (either newly diagnosed or those patients with a history of hypertension but have not been taking any antihypertensive drugs for at least 4 weeks prior to first visit) must have an offcie msSBP ≥ 150 mmHg and \< 180 mmHg at screening and 1 week after screening and must have an office msSBP ≥ 145 mmHg and \< 180 mmHg after 4 weeks run-in epoch~* patients must successfully complete ABPM and pass technical requirements to be qualified for randomization~Exclusion Criteria:~* Malignant or severe hypertension (grade 3 of WHO classification; msDBP ≥110 mmHg and/or msSBP ≥ 180 mmHg)~* History of angioedema, drug-related or otherwise~* History or evidence of a secondary form of hypertension, including but not limited to any of the following: renal parenchymal hypertension, renovascular hypertension (unilateral or bilateral renal artery stenosis), coarctation of the aorta, primary hyperaldosteronism, Cushing's disease, pheochromocytoma, polycystic kidney disease (PKD), drug-induced hypertension~* Patients who previously entered a LCZ696 study and had been randomized or enrolled to receive active drug treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LCZ696 200 mg (Type: EXPERIMENTAL): Patients will be treated with one LCZ696 200 mg tablet and one placebo of olmesartan 20 mg capsule once daily for 8 weeks.
- Olmesartan 20 mg (Type: ACTIVE_COMPARATOR): Patients will be treated with one placebo of LCZ696 200 mg tablet and one olmesartan 20 mg capsule once daily for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients of any age undergoing allogeneic or autologous HCT~* Histologic TMA diagnosis OR clinical TMA diagnosis and presenting with high risk disease features including elevated plasma sC5b-9 above laboratory normal value (≥244ng/ml) and proteinuria measured as ≥30mg/dL of protein on random urinalysis x2 or protein/creatinine ratio ≥1mg/mg or patient receiving renal replacement therapy.~* Minimum weight of ≥ 5kg.~Exclusion Criteria:~* Known hypersensitivity to any constituent of the study medication.~* Subjects with unresolved serious Neisseria meningitides infection or progressive severe infection.~* Patients with diagnosis of TTP as defined by ADAMST13 activity test \<10%.~* Patients previously treated with eculizumab or other complement blocker for TMA within the 60 days prior to first dose of study treatment.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eculizumab (Type: EXPERIMENTAL): All patients will receive eculizumab based on their weight for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improving Medication Adherence Among Underserved Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults aged 18 years and older~* Individuals who have received a diagnosis for type 2 diabetes mellitus~* Enrolled as a patient at a participating community health center~* Individuals currently being treated with oral and/or injectable diabetes medications~Exclusion Criteria:~* Non-English speakers~* Individuals who report they do not have a cell phone~* Individuals unwilling and/or not able to provide written informed consent~* Individuals with unintelligible speech (e.g., dysarthria)~* Individuals with a severe hearing or visual impairment~* Individuals who report a caregiver administers their diabetes medications Individuals who fail the cognitive screener administered during the baseline survey~* Individuals who cannot receive, read, and respond to a text after instruction from a trained research assistant~* Individuals whose most recent (within 12 months) HbA1c value was 6.8% or greater

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- REACH (Type: EXPERIMENTAL): Participants will receive REACH text messages (individual-focused text messaging tailored to user's individual barriers to adherence and targeted to address other self-care behaviors) for 12 months.~All participants will also receive text messages advising how to access their study A1c test results, receive quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions.
- REACH + FAMS (Type: EXPERIMENTAL): In addition to the REACH text messages tailored to user's individual barriers to adherence, participants will receive FAMS components (monthly phone coaching and text messages supporting a goal set in coaching, plus the option to invite a family member/support person to receive text messages) for six months. After six months, participants in this arm will receive REACH text messages only.~All participants will also receive text messages advising how to access their study A1c test results, receive quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions.
- Helpline and A1c results (Type: ACTIVE_COMPARATOR): Participants assigned to the control group will complete measures at each time point and maintain care as usual (i.e., medical treatment and physician monitoring).~All participants will receive text messages advising how to access their study A1c test results, receive quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: EPAT: Estrogen in the Prevention of Atherosclerosis Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal female (serum estradiol less than 20 pg/ml)~* 46 to 80 years old~* Fasting LDL-C levels 130 to 210 mg/dL~* Triglyceride levels less than 400 mg/dL~* Current non-smoker~Exclusion Criteria:~* Clinical evidence of cardiovascular disease~* HDL-C level less than 30 mg/dL~* Fasting blood glucose greater than 200 mg/dL~* Previous hormonal replacement therapy (non-contraceptive) over 10 years duration and/or current use within 1 month~* Uncontrolled hypertension~* Untreated thyroid disease~* Renal insufficiency~* Clinical evidence of congestive heart failure~* Life threatening disease with prognosis less than 5 years~* Alcohol intake greater than 5 drinks per day (1 drink = 1 1/2 oz distilled spirits, 4 oz wine, or 12 oz beer) or substance abuse (intravenous drug abuse, cocaine use)~* History of estrogen dependent cancer or detected at screening or any other disorder precluding use of ERT~* Hot flashes greater than 5 per day which interfere with daily activity and preclude randomization to placebo.

- Gender: FEMALE
- Minimum Age: 46 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Flovent in Patients With Eosinophilic Esophagitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent for study by subject, or parent/guardian if subject is a minor. Assent will be obtained from all minors 11 years of age and older.~* Histological findings on esophageal biopsy to include peak eosinophil density ≥ 24 per high power field (400x) in the proximal or distal esophagus validated by a pathologist at CCHMC.~* Allergy evaluation including skin-prick testing with multiple food antigens to ensure elimination diet is not indicated.~* Have undergone a minimum 3 months of elimination diet as indicated by skin-prick testing without detectable resolution by repeat endoscopy with biopsies demonstrating persistent EE OR subject/parental refusal to follow elimination diet. If the subject/parent refuses the elimination diet, they are eligible for this study.~* Treatment with a proton-pump inhibitor for at least two months (rounded to nearest month) prior to endoscopy OR failure of histological improvement as defined by \< 1 eosinophil per HPF after 2 month (rounded to nearest month) trial of proton pump inhibitor documented by prior endoscopy. The PPI must be used prior to endoscopy to rule out the possibility of GERD.~Exclusion Criteria:~* History of poor tolerance to Fluticasone Propionate (FP), as defined as multiple episodes of oral candidiasis, hypothalamic-pituitary-adrenal axis suppression as evidenced by signs of Cushing syndrome, headaches, or increased respiratory infections during exposure to Flovent~* Unable to cooperate with use of MDI~* Pregnant females~* Concurrent or recent (within 3 months) use of systemic corticosteroids.~* Unable to swallow medicines (i.e., fed only by gastrostomy tube).~* Comorbid eosinophilic disorders.~* Previously treated with swallowed glucocorticoid for EE within 3 months of the screening visit. Nasal glucocorticoids taken for EE are permitted.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Flovent 1760 mcg (Type: EXPERIMENTAL): Fluticasone propionate 880 mcg twice daily for 3 months
- Placebo (Type: PLACEBO_COMPARATOR): Placebo twice daily for 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Relapsed/refractory, pathologically confirmed EBV+ lymphoid malignancy or lymphoproliferative disease~* Absence of available therapy with reasonable likelihood of cure or significant clinical benefit~* Adequate hematologic, hepatic and renal function as defined by laboratory assessment~Key Exclusion Criteria:~* Known primary CNS lymphoma~* Known CNS metastases or leptomeningeal disease unless appropriately treated and neurologically stable for at least 4 weeks~* Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy~* Refractory graft versus host disease (GvHD) not responding to treatment~* Known active hepatitis B virus infection~* Circulating hepatitis C virus on qPCR~* Known history of HHV-6 chromosomal integration~* Known history of HIV infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1b Dose Escalation (Type: EXPERIMENTAL): VRx-3996 (cohort 1) and valganciclovir~VRx-3996 (cohort 2) and valganciclovir~VRx-3996 (cohort 3) and valganciclovir~VRx-3996 (cohort 4) and valganciclovir~VRx-3996 (cohort 5) and valganciclovir
- Phase 2 Dose Expansion (Type: EXPERIMENTAL): VRx-3996 (RP2D: recommended phase 2 dose) and valganciclovir
- PK Cohort (Type: EXPERIMENTAL): Assessment of VRx-3996 tablet and valganciclovir PK parameters at the RP2D

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed primary hepatocellular carcinoma (HCC)~* Inoperable disease (T2-T4, any N, M0 or M1) or refused surgery~* Measurable disease~* At least 1 bidimensionally measurable lesion of at least 2 cm by computed tomography (CT) scan or magnetic resonance imaging (MRI)~* Presence of at least 1 of the following:~* Alpha-fetoprotein greater than the upper limit of normal (ULN)~* Hepatitis C antibody positive~* Hepatitis B surface antigen positive~* Child's Pugh class A or B~* Candidate for systemic therapy~Exclusion Criteria:~* Fibrolamellar disease mixed histology~* Metastatic brain or meningeal tumors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sorafenib 400 mg b.i.d. (Type: EXPERIMENTAL): Sorafenib (Nexavar, BAY43-9006) 400 mg administered bis in die (bid, twice a day)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Carbetocin at Elective Cesarean Delivery Part 2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* All patients planned for elective cesarean delivery under spinal anesthesia.~* All patients who give written informed consent to participate in this study.~Exclusion Criteria:~* All patients who refuse to give written informed consent.~* All patients who claim allergy or hypersensitivity to carbetocin or oxytocin.~* All patients with conditions that predispose to uterine atony and postpartum hemorrhage such as placenta previa, multiple gestation, preeclampsia, eclampsia, macrosomia, polyhydramnios, uterine fibroids, previous history of uterine atony and postpartum bleeding, or bleeding diathesis.~* All patients with hepatic, renal, and vascular disease,~* All patients requiring general anesthesia prior to the administration of the study drug.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Carbetocin 20mcg (Type: ACTIVE_COMPARATOR): None
- Carbetocin 40mcg (Type: ACTIVE_COMPARATOR): None
- Carbetocin 60mcg (Type: ACTIVE_COMPARATOR): None
- Carbetocin 80mcg (Type: ACTIVE_COMPARATOR): None
- Carbetocin 100mcg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete